Elevated levels of a specific protein found to correlate with inflammatory symptom severity in COVID

July 24, 2020

A new study found raised levels of transforming growth factor beta-induced protein (TGFBIp) in blood sampled from roughly 100 people hospitalized for COVID-19, and further found that elevated levels of both the normal and acetylated forms of TGFBIp correlated with the severity of disease symptoms in these patients. While more work will be required to determine whether heightened levels of acetylated TGFBIp can serve as an exclusive, specific, and reliable diagnostic indicator for the severity of COVID-19, the research also suggests that TGFBIp could be a viable therapeutic target to treat severe inflammation - including deadly "cytokine storms" - in patients suffering from severe cases of the disease. While much work has been done to characterize the immune responses of patients with COVID-19, the inflammatory markers and cytokines known to be induced by SARS-CoV-2 infection are often short-lived. Hee Ho Park and colleagues set out to investigate whether increased levels of both the normal and acetylated forms of TGFBIp, a more stable molecule known to activate the immune-regulating transcription factor NF-κB, might serve as a more lasting signal of SARS-CoV-2 infection. The researchers analyzed blood samples from healthy controls and two cohorts of COVID-19 patients: those admitted to a hospital for treatment with relatively mild symptoms, and those who required ICU care to treat acute respiratory distress syndrome (ARDS) and/or sepsis. Compared with the healthy controls, both patient cohorts exhibited elevated levels of TGFBIp, as well as higher levels of acetylated TGFBIp, with the ICU patients exhibiting even greater levels of both protein forms. Upon treating immune cells taken from these patients with antibodies that neutralize TGFBIp, the researchers also observed a decrease in the production of inflammatory cytokines. While further work will be required to validate these results and assess the safety of the neutralizing antibodies, the finding nonetheless suggests that TGFBIp could be targeted to help treat severe inflammation in COVID-19 patients.

American Association for the Advancement of Science

Related Cytokines Articles from Brightsurf:

Uracil switch in SARS-CoV-2 genome alters innate immune responses
Our bodies could be inducing mutations in the COVID-19 virus that activate immune cells to increase the production of pro-inflammatory molecules.

Oncotarget: Th1 cytokines potentiate apoptosis of breast cancer cells and suppress tumor growth
Volume 11, Issue 30 of Oncotarget reported that previously, the authors showed that anti-estrogen drugs combined with a dendritic cell-based anti-HER-2 vaccine known to induce strong Th1-polarized immunity dramatically improved clinical response rates in patients with HER-2pos/ERpos early breast cancer.

A bifidobacterial protein that can reduce inflammation in COVID-19 found by a RUDN geneticist
A geneticist from RUDN University studied the effect of Bifidobacterium (intestinal bacteria) on the inflammatory process and discovered that their surface protein is capable of stopping excessive or uncontrollable inflammation, like the one observed in COVID-19 patients.

Does the COVID-19 cytokine storm exist?
Cytokines play a crucial role in the immune response. If this immune response is too strong, also known as ''cytokine storm'', it can cause harm to the patient.

St18 is a negative regulator of VEGF
A research team led by Kenta Maruyama M.D., Ph.D. from National Institute for Physiological Sciences explored the role of St18 in the regulation of VEGF expression.

Cytokine implicated in HLH treatment resistance
Research sheds light on cytokine storm syndromes and how ruxolitinib may benefit patients with hemophagocytic lymphohistiocytosis.

Proteins may halt the severe cytokine storms seen in COVID-19 patients
A team of MIT researchers has developed specialized antibody-like receptor proteins that they believe could soak up the excess cytokines produced during a cytokine storm.

Cancer: The immune system attacks tumors remotely
How does the immune system act to limit tumor development?

Scientists discover how rogue communications between cells lead to leukemia
New research has deciphered how rogue communications in blood stem cells can cause leukemia.

Secretome of pleural effusions associated with non-small cell lung cancer (NSCLC) and malignant...
Cryopreserved cell-free PE fluid from 101 NSCLC patients, 8 mesothelioma and 13 with benign PE was assayed for a panel of 40 cytokines/chemokines using the Luminex system.

Read More: Cytokines News and Cytokines Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.